Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (501-510 of 869) with videos related to

Pageof 87
Sort By:
Blood|February 12, 2005
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivoMakoto Hamasaki, Teru Hideshima, Pierfrancesco Tassone, et al.
The Journal of Clinical Investigation|March 5, 2013
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progressionAldo M Roccaro, Antonio Sacco, Patricia Maiso, et al.
British Journal of Haematology|April 25, 2007
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
British Journal of Haematology|December 19, 2006
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growthHiroshi Yasui, Teru Hideshima, Hiroshi Ikeda, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Longitudinal genetically detectable minimal residual disease by fluorescence <i>in situ</i> hybridization confers a poor prognosis in myelomaJian Cui, Tengteng Yu, Rui Lv, et al.
Blood|December 3, 2003
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironmentKlaus Podar, Laurence P Catley, Yu-Tzu Tai, et al.
International Journal of Cancer|December 19, 2022
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemiaDanka Cholujova, Gabor Beke, Zachary R Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple MyelomaDavid S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
Cancer Research|March 15, 2024
Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical ImplicationsYu-Tzu Tai, Laurence P Catley, Constantine S Mitsiades, et al.
Cancer Research|September 5, 2002
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine modelRichard LeBlanc, Laurence P Catley, Teru Hideshima, et al.
Pageof 87

Showing results (501-510 of 869) with videos related to

Sort By:
Pageof 87
Blood|February 12, 2005
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivoMakoto Hamasaki, Teru Hideshima, Pierfrancesco Tassone, et al.
The Journal of Clinical Investigation|March 5, 2013
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progressionAldo M Roccaro, Antonio Sacco, Patricia Maiso, et al.
British Journal of Haematology|April 25, 2007
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
British Journal of Haematology|December 19, 2006
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growthHiroshi Yasui, Teru Hideshima, Hiroshi Ikeda, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Longitudinal genetically detectable minimal residual disease by fluorescence <i>in situ</i> hybridization confers a poor prognosis in myelomaJian Cui, Tengteng Yu, Rui Lv, et al.
Blood|December 3, 2003
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironmentKlaus Podar, Laurence P Catley, Yu-Tzu Tai, et al.
International Journal of Cancer|December 19, 2022
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemiaDanka Cholujova, Gabor Beke, Zachary R Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple MyelomaDavid S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
Cancer Research|March 15, 2024
Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical ImplicationsYu-Tzu Tai, Laurence P Catley, Constantine S Mitsiades, et al.
Cancer Research|September 5, 2002
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine modelRichard LeBlanc, Laurence P Catley, Teru Hideshima, et al.
Pageof 87